Terns sold to Merck for 13% lower than pharma's initial offer because of clinical data
由于临床数据影响，默克以比其最初报价低13%的价格收购Terns

Although Merck and Terns Pharmaceuticals are part of biotech’s M&A surge, the $6.7 billion deal didn’t nearly play out the way either anticipated.
尽管默克与Terns都参与了生物科技领域的并购热潮，但这笔67亿美元的交易几乎完全没有按照双方的预期发展。